Avid Bioservices Maintains FY24 Revenue Guidance Of $137M-$147M, Est $138.656M
Portfolio Pulse from Benzinga Newsdesk
Avid Bioservices has reaffirmed its fiscal year 2024 revenue guidance, maintaining the forecast in the range of $137 million to $147 million, closely aligning with the estimated $138.656 million.
April 24, 2024 | 9:40 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Avid Bioservices, trading under the symbol CDMO, has confirmed its revenue guidance for fiscal year 2024, projecting revenues to be between $137 million and $147 million.
Reaffirming revenue guidance, especially when it aligns with or exceeds market estimates, can positively influence investor sentiment and stock price. For Avid Bioservices, maintaining its revenue forecast in the expected range demonstrates stability and potential growth, likely leading to a positive short-term impact on its stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 90